Risk of potential hepatotoxicity from pirfenidone or nintedanib in patients with idiopathic pulmonary fibrosis: results of a retrospective analysis of a large insurance database in Taiwan

Background: A growing population of individuals diagnosed with idiopathic pulmonary fibrosis (IPF) are receiving treatment with nintedanib and pirfenidone. The aim of our study was to assess the incidence of drug-induced liver injury (DILI) associated with the use of pirfenidone and nintedanib in pa...

Full description

Bibliographic Details
Published in:	Frontiers in Pharmacology
Main Authors:	Kuang-Ming Liao, Chung-Yu Chen
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-02-01
Subjects:	idiopathic pulmonary fibrosis nintedanib pirfenidone drug-induced liver injury hepatotoxicity
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1309712/full

Similar Items

Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre
by: E. Bargagli, et al.
Published: (2019-05-01)

Comparison of the Effects of Nintedanib and Pirfenidone on Pulmonary Function Test Parameters and Radiological Findings in Patients with Idiopathic Pulmonary Fibrosis: A Real-Life Study
by: Olcay Aycicek, et al.
Published: (2025-02-01)

Efficacy and safety of combination therapy with pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
by: Jin-Young Huh, et al.
Published: (2023-12-01)

The role of nintedanib and pirfenidone in the treatment of idiopathic pulmonary fibrosis and review of recent clinical trials of IPF therapy
by: Michał Żuber, et al.
Published: (2024-06-01)

Effects of Pirfenidone and Nintedanib on Markers of Systemic Oxidative Stress and Inflammation in Patients with Idiopathic Pulmonary Fibrosis: A Preliminary Report
by: Alessandro G. Fois, et al.
Published: (2020-10-01)

Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
by: Kazutaka Takehara, et al.
Published: (2022-01-01)

Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows
by: Maria Chianese, et al.
Published: (2024-05-01)

Bibliometric analysis of the pirfenidone and nintedanib in interstitial lung diseases
by: Jia Liu, et al.
Published: (2024-04-01)

Nintedanib and pirfenidone for idiopathic pulmonary fibrosis in King Abdulaziz Medical City, Riyadh: Real-life data
by: Mohammed Ayaz Khan, et al.
Published: (2023-01-01)

Long-term treatment with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a comparative, real-world cohort study
by: Francesca Lalla, et al.
Published: (2025-10-01)

Comparative Long-term Effects of Nintedanib and Pirfenidone in Idiopathic Pulmonary Fibrosis: A Real-life Study with Five-year Follow-up
by: Ayça Yanalak, et al.
Published: (2025-11-01)

Comparison of reversal of rat pulmonary fibrosis of nintedanib, pirfenidone, and human umbilical mesenchymal stem cells from Wharton’s jelly
by: Kuo-An Chu, et al.
Published: (2020-11-01)

Can Pirfenidone and Nintedanib Be Alternative Treatment Options for Radiation Pneumonitis?
by: Hikmet COBAN, et al.
Published: (2025-06-01)

Comparison of the safety profiles for pirfenidone and nintedanib: a disproportionality analysis of the US food and drug administration adverse event reporting system
by: Xiangyu Sun, et al.
Published: (2024-05-01)

Antifibrotics and mortality in idiopathic pulmonary fibrosis: external validity and avoidance of immortal time bias
by: Hironao Hozumi, et al.
Published: (2024-07-01)

Idiopathic pulmonary fibrosis: the turning point is now!
by: Manuela Funke, et al.
Published: (2015-05-01)

Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States
by: Timothy M. Dempsey, et al.
Published: (2022-01-01)

Therapeutic efficacy of pirfenidone and nintedanib in pulmonary fibrosis; a systematic review and meta-analysis
by: Yiting Qiu, et al.
Published: (2025-07-01)

NICEFIT—A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan
by: Shih-Lung Cheng, et al.
Published: (2022-09-01)

The Management of Patients With Idiopathic Pulmonary Fibrosis
by: Paolo Spagnolo, et al.
Published: (2018-07-01)

Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries
by: Ida Pesonen, et al.
Published: (2018-05-01)

Choice of Methodology Impacts Outcome in Indirect Comparisons of Drugs for Idiopathic Pulmonary Fibrosis
by: David A. Scott, et al.
Published: (2019-08-01)

Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis
by: Mareike Lehmann, et al.
Published: (2018-09-01)

Cost-effectiveness of pirfenidone compared to all available strategies for the treatment of idiopathic pulmonary fibrosis in France
by: Emilie Clay, et al.
Published: (2019-01-01)

Real world experience on the effectiveness and safety of pirfenidone in patients with idiopathic pulmonary fibrosis in Taiwan
by: Cheng-Yu Chang, et al.
Published: (2023-10-01)

Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results
by: Goran Nadir Salih, et al.
Published: (2016-09-01)

Analysis of treatment efficacy, tolerability, and survival of patients receiving antifibrotic therapy for progressive nonidiopathic pulmonary fibrosis
by: Nesrin Ocal, et al.

Drug-Induced Thrombocytopenia Due to Nintedanib during Treatment of Idiopathic Pulmonary Fibrosis
by: Igor Dumic, et al.
Published: (2023-05-01)

Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece
by: Argyrios Tzouvelekis, et al.
Published: (2017-11-01)

Effects of Pirfenidone on Idiopathic Pulmonary Fibrosis Progression and Safety: Results of Multicenter Prospective Observational Study
by: Sergey Avdeev, et al.
Published: (2023-02-01)

Corrigendum: Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece
by: Argyrios Tzouvelekis, et al.
Published: (2018-01-01)

Long-Term Safety of Antifibrotic Drugs in IPF: A Real-World Experience
by: Stefano Levra, et al.
Published: (2022-12-01)

Pirfenidone Improves Familial Idiopathic Pulmonary Fibrosis without Affecting Serum Periostin Levels
by: Yasuhiko Koga, et al.
Published: (2019-05-01)

Real-world treatment persistence and predictive factors for discontinuation of antifibrotic therapies in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of two multicenter observational cohort studies in Poland
by: Sebastian Majewski, et al.
Published: (2025-06-01)

Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system database and the Japanese adverse drug event report databases
by: Tao Wang, et al.
Published: (2025-04-01)

The Impact of Comorbidities on the Discontinuation of Antifibrotic Therapy in Patients with Idiopathic Pulmonary Fibrosis
by: Stefano Kette, et al.
Published: (2025-03-01)

Metformin enhanced the effect of pirfenidone on pulmonary fibrosis in mice
by: Nana Liu, et al.
Published: (2024-01-01)

Efficacy of Pirfenidone According to Dose in Patients with Idiopathic Pulmonary Fibrosis: A Prospective, Observational, Single-Center Cohort Study
by: Ho Young Lee, et al.
Published: (2023-10-01)

Treatable traits in idiopathic pulmonary fibrosis: focus on respiratory tract infections—a systematic review and a meta-analysisResearch in context
by: Zsombor Matics, et al.
Published: (2025-01-01)

The safety and tolerability of pirfenidone in Indian patients with idiopathic pulmonary fibrosis
by: Avinash Anil Nair, et al.
Published: (2022-01-01)